RAMAT GAN, Israel--(BUSINESS WIRE)--Optimata Ltd. announced today the successful results of a clinical study for the prediction of individualized patient response to chemotherapy drugs. The study used Optimata's computerized technology known as the Virtual Cancer Patient Engine (VCP).
